There are 3161 resources available
900P - Notch inhibitor AL101 prior to surgery in patients (pts) with Notch1 activated adenoid cystic carcinoma (ACC): Safety and efficacy in a window of opportunity study
Presenter: Renata Ferrarotto
Session: Poster session 02
901P - A phase II trial of neoadjuvant nivolumab, docetaxel, and cisplatin therapy followed by surgery and radiation therapy for resectable high-grade salivary gland carcinoma
Presenter: Sehhoon Park
Session: Poster session 02
902P - Comparison of progression free and overall survival (OS) with bicalutamide and 4-weekly or 12-weekly triptorelin in androgen receptor positive (AR+) salivary gland cancer (SGC)
Presenter: Amelia Handley
Session: Poster session 02
903P - Patterns and predictors of recurrence-free survival (RFS) in salivary gland cancers (SGCs): A Spanish multicenter study
Presenter: Alexandre Izquierdo Miranda
Session: Poster session 02
904P - Analysis of TP63 immunohistochemistry scores (IHC) by primary site and between primary and metastatic tumours in adenoid cystic carcinoma (ACC)
Presenter: Laura Spurgeon
Session: Poster session 02
905P - Validation of MYC/TP63 classification for adenocystic carcinomas of salivary glands
Presenter: Panagiota Economopoulou
Session: Poster session 02
906P - Prognostic impact and therapeutic implications of comprehensive genomic profiling (CGP) in non-metastatic salivary gland cancers (nmSGC)
Presenter: Mario Balsa Pena
Session: Poster session 02
907P - Biomarker analysis of the phase III KEYNOTE-040 study of pembrolizumab (pembro) versus methotrexate, docetaxel, or cetuximab (SOC) for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC)
Presenter: Denis Soulieres
Session: Poster session 03
909P - Immunoscore-IC predicts nivolumab efficacy as adjuvant treatment after salvage surgery in head and neck cancer squamous cell carcinoma: The ADJORL1 trial
Presenter: Alix Marhic
Session: Poster session 03